photo of

Details

Role Biostatistician (Snr Research Officer)
Research area Population Health
Group Clinical Epidemiology & Biostatistics (CEBU)
Marnie joined the Clinical Epidemiology and Biostatistics Unit (CEBU) as a postdoctoral biostatistician in 2020 after completing her PhD in Biostatistics at the University of Melbourne. Marnie supports a number of research streams at MCRI including COVID Wellbeing and Changing Children's Chances where she provides input on epidemiological design and statistical methods to single- and multi-cohort research projects. Her expertise is underpinned by methodological research in causal inference, conducted as part of the causal team within CEBU.

Marnie has previous experience working at the University of Melbourne Statistical Consulting Centre (2005-2010) and the Centre for Biostatistics and Clinical Trials at Peter MacCallum Cancer Centre (2010-2014).
Marnie joined the Clinical Epidemiology and Biostatistics Unit (CEBU) as a postdoctoral biostatistician in 2020 after completing her PhD in Biostatistics at the University of Melbourne. Marnie supports a number of research streams at MCRI including...
Marnie joined the Clinical Epidemiology and Biostatistics Unit (CEBU) as a postdoctoral biostatistician in 2020 after completing her PhD in Biostatistics at the University of Melbourne. Marnie supports a number of research streams at MCRI including COVID Wellbeing and Changing Children's Chances where she provides input on epidemiological design and statistical methods to single- and multi-cohort research projects. Her expertise is underpinned by methodological research in causal inference, conducted as part of the causal team within CEBU.

Marnie has previous experience working at the University of Melbourne Statistical Consulting Centre (2005-2010) and the Centre for Biostatistics and Clinical Trials at Peter MacCallum Cancer Centre (2010-2014).

Top Publications

  • Mantha, S, Goldman, DA, Devlin, SM, Lee, J-W, Zannino, D, Collins, M, Douer, D, Iland, HJ, Litzow, MR, Stein, EM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 129(13) : 1763 -1767 2017
    view publication
  • Spittal, MJ, Carlin, JB, Currier, D, Downes, M, English, DR, Gordon, I, Pirkis, J, Gurrin, L. The Australian longitudinal study on male health sampling design and survey weighting: implications for analysis and interpretation of clustered data. BMC Public Health 16(Suppl 3) : 1062 2016
    view publication
  • Iland, HJ, Collins, M, Bradstock, K, Supple, SG, Catalano, A, Hertzberg, M, Browett, P, Grigg, A, Firkin, F, Campbell, LJ, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology 2(9) : e357 -e366 2015
    view publication
  • Shah, K, Marvelde, LT, Collins, M, De Abreu Lourenco, R, D’Costa, I, Coleman, A, Fua, T, Liu, C, Rischin, D, Lau, E, et al. Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. Oral Oncology 51(5) : 529 -535 2015
    view publication
  • Lim, ABM, Storek, J, Beligaswatte, A, Collins, M, Tacey, M, Williamson, T, Mason, K, Li, E, Chaudhry, MA, Russell, JA, et al. Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. Bone Marrow Transplantation 50(4) : 566 -572 2015
    view publication

Page 6 of 15

Related links